Napyradiomycin B4
Napyradiomycin B4 is a Napyradiomycin derivative, which inhibits the RANKL-induced MEK-ERK signaling pathway. Napyradiomycin B4 attenuates osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 111216-63-8
- 分子式: C25H31Cl3O6
- 分子量:533.87
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MEK アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
10 μM
Compound: napyradiomycin B4
|
Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTS assay
Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTS assay
|
[PMID: 24328269] |
体外実験
Napyradiomycin B4 (5 μM, 4 days) inhibits RANKL-induced osteoclast differentation[1].
Napyradiomycin B4 (5 μM, 4 days) promotes the expressions of Nrf2 related genes and inhibits the expressions of osteoclast related genes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BMMs
-
Concentration:1-5 μM
-
Incubation Time:4 days
-
Result:Revealed no evidence of F-actin ring.
-
Cell Line:BMMs
-
Concentration:1-5 μM
-
Incubation Time:4 days
-
Result:Reduced mRNA expressions of Nfatc1, Acp5, Dcstamp, Ctsk, and Mmp9.
Promoted mRNA expressions of Nrf2, Nqo1 and HO1.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Ligature-induced periodontitis in C57BL/J6 mice model[1]
-
Dosage:2-12 mg/kg
-
Administration:i.p. for 6 days
-
Result:Prevented the alveolar bone resorption and bone loss with high dose, inhibited osteoclast formation.
化学情報
-
CAS 番号 111216-63-8
-
分子量 533.87
-
分子式 C25H31Cl3O6
-
SMILES
Cl[C@](C(C1=C(O)C=C(O)C=C1C2=O)=O)(C[C@H](C(C)(O3)C)Cl)[C@]23C[C@H]4C(C)([C@H](CC[C@@]4(O)C)Cl)C
-
Initial Source
marine-derived Streptomyces species
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Osteoclast differentiation from monocyte/macrophage precursors
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Napyradiomycin B4 関連分類
HY-N12740 関連分類
Powered by Bioz